Related Experiment Video
Updated: Jun 5, 2026
07:54
Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence
Published on: October 25, 2011
Ixabepilone development across the breast cancer continuum: a paradigm shift
1Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Cancer Management and Research
|December 29, 2010
Summary
Ixabepilone offers a new option for advanced breast cancer, overcoming resistance to other therapies. This epothilone analog shows promise in extending progression-free survival for patients with limited treatment choices.
Area of Science:
- Oncology
- Pharmacology
- Medical Therapeutics
Background:
- Taxanes and anthracyclines are limited by tumor survival mechanisms.
- Ixabepilone, an epothilone analog, demonstrates reduced susceptibility to these resistance pathways.
- Existing treatments for advanced breast cancer have limitations, necessitating novel therapeutic approaches.
Purpose of the Study:
- To evaluate the efficacy of ixabepilone as a single agent and in combination for advanced and early-stage breast cancer.
- To assess ixabepilone's effectiveness in patients resistant to or who have failed prior therapies.
- To investigate the safety and tolerability profile of ixabepilone.
Main Methods:
- Clinical studies evaluating ixabepilone as a single agent and in combination regimens.
- Assessment of treatment outcomes in metastatic and early-stage breast cancer patients.
- Analysis of response in patients with resistance to anthracyclines, taxanes, or capecitabine.
Main Results:
- Ixabepilone showed promise in metastatic breast cancer post-failure of standard therapies.
- Combination therapy with ixabepilone and capecitabine reduced disease progression risk by 25% in resistant patients.
- Triple-negative tumors were particularly responsive to the ixabepilone-capecitabine doublet.
Conclusions:
- Ixabepilone is a valuable addition to advanced breast cancer treatment options.
- The drug demonstrates efficacy in heavily pretreated patients and may extend progression-free survival.
- Manageable toxicities support ixabepilone's integration into diverse treatment settings.
Related Concept Videos
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:28Preclinical Development: Overview
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:26Drug Administration and Therapy Phases: Overview
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...